Ignite Creation Date:
2024-05-06 @ 3:39 AM
Last Modification Date:
2024-10-26 @ 11:37 AM
Study NCT ID:
NCT02349698
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2015-01-25
Brief Title:
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of Chimeric Antigen Receptor CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this research is to verify the safety of CD19 targeted chimeric antigen receptor T cells and to determine the proper dosage of CAR T cells infused
Detailed Description:
Nowadays refractory or relapsed leukemialymphoma lacks effective treatment Innovative therapy is urgently required Chimeric antigen receptor CAR-modified T cells have demonstrated great successes in treating even late stage cluster of differentiation antigen 19 CD19 positive B cell malignancies To design better CAR T cells we have developed new CD19 CARs Preclinical studies have demonstrated effective killing of CD19 target cells In this study the CD19 CARs will be evaluated in CD19 positive leukemialymphoma patients The primary goal is to confirm its adverse effects including cytokine storm response and any other adverse effects In addition tumor targeting and disease status after treatment will also be evaluated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None